Oral use. Should be taken 15-30 minutes before meals. Do not exceed the recommended dose.

Domperidone acts as a peripheral dopamine D2 receptor antagonist, primarily in the chemoreceptor trigger zone (CTZ) and the gastrointestinal tract. This action blocks dopamine-induced emesis and enhances gastrointestinal motility.

• •Known hypersensitivity to Domperidone
• •Patients with prolactin-releasing pituitary tumor
• •Patients with moderate to severe hepatic impairment
• •Patients with known prolongation of cardiac QTc intervals
• •Co-administration with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin)

Store below 30°C, protected from light and moisture. Do not freeze.

Symptoms of overdose include drowsiness, disorientation, extrapyramidal reactions, and potential cardiac effects. Management is symptomatic and supportive, including gastric lavage and activated charcoal. ECG monitoring is recommended.

Pregnancy Category C. Use during pregnancy only if clearly needed and the potential benefits outweigh the risks. Domperidone is excreted in breast milk; therefore, use is generally not recommended during lactation, especially if cardiac risks for the infant are a concern.